title: Studies on biliary tract carcinoma in the case with pancreaticobiliary maljunction.
abstract: OBJECTIVE
  The purpose of this study was to clarify the clinicopathological features of pancreaticobiliary maljunction and to determine the appropriate surgical approach for biliary tract with pancreaticobiliary maljunction.
  
  
  METHODS
  The data of 77 patients with pancreaticobiliary maljunction including 13, who had been treated for biliary tract cancer, were reviewed retrospectively. We assessed the clinical features, biological characteristics of the cancer, methods of surgical treatment, postoperative outcome and cell proliferating activity of the biliary epithelium, evaluated by the PCNALI (proliferating cell nuclear antigen-labeling index).
  
  
  RESULTS
  The incidence of cancer development in the case with pancreaticobiliary maljunction was 13.4% in the bile duct dilatation group (n = 67) and 40.0% in the non-dilatation group (n = 10). Dissection of lymphadenectomy was performed in 10 (76.9%) of 13 patients, and curative resection was feasible in 9 of the 10 patients. Two (20.0%) of the 10 patients had lymph node involvement noted at surgery and died of recurrence. In the other eight patients without lymph node involvement at surgery, six patients underwent curative resection and are alive at 7 months to 11 years and 6 months after surgery. PCNALI of the biliary epithelium of the patients with pancreaticobiliary maljunction was significantly higher than that of the control group.
  
  
  CONCLUSIONS
  For patients with pancreaticobiliary maljunction, it should be stressed that the extrahepatic bile duct be prophylactically removed, even when there are no neoplasmatic changes because of high prevalence of cancer development, presumably predicted by the increase of cell proliferative activity in the biliary epithelium. For patients with biliary cancer, early detection at the stage with no lymph node involvement is essential to secure for long-term survival.
authors.affiliation: Department of General and Gastroenterological Surgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan. sur049@poh.osaka-med.ac.jp
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Hara
authors.forename: Shinsho
authors.initials: S
authors.lastname: Morita
authors.forename: Takashi
authors.initials: T
authors.lastname: Ishibashi
authors.forename: Shozo
authors.initials: S
authors.lastname: Sako
authors.forename: Takehiko
authors.initials: T
authors.lastname: Dohi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Otani
authors.forename: Mitsuhiko
authors.initials: M
authors.lastname: Iwamoto
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Inoue
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Tanigawa
mesh_terms: D000328:Adult; D000368:Aged; D001652:Bile Ducts / Q000002:abnormalities; D003137:Common Bile Duct Diseases / Q000150:complications* / Q000151:congenital* / Q000601:surgery; D003138:Common Bile Duct Neoplasms / Q000150:complications* / Q000473:pathology / Q000601:surgery; D005260:Female; D005706:Gallbladder Neoplasms / Q000150:complications* / Q000473:pathology / Q000601:surgery; D006801:Humans; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D010179:Pancreas / Q000002:abnormalities; D010182:Pancreatic Diseases / Q000150:complications* / Q000151:congenital* / Q000601:surgery; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D018809:Proliferating Cell Nuclear Antigen